Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion type Assertion NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_head.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion wasGeneratedBy ECO_0000203 NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion wasDerivedFrom befree-2016 NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion SIO_000772 18048643 NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion evidence source_evidence_literature NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.
- NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_assertion description "[Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP642703.RAtamw5fvWjV2G5tCLnZxU9WpT8L5M2coHyVQpFnHt4Zw130_provenance.